no-difference-in-kidney-transplantation-outcomes-for-HIV-positive-recipients-regardless-of-donor-HIV-status

No difference in kidney transplantation outcomes for HIV-positive recipients regardless of donor HIV status

Human immunodeficiency virus (HIV) has been transformed into a chronic disease to the successful introduction of antiretroviral therapy (ART), and people living with HIV (PWH) now experience morbidity from other chronic conditions, such as kidney, liver, and heart disease.

interim-results-of-a-Phase-2b-3-trial-investigating-a-long-acting-injectable-of-cabotegravir-for-pre-exposure-prophylaxis-of-HIV

Interim results of a Phase 2b/3 trial investigating a long-acting injectable of cabotegravir for pre-exposure prophylaxis of HIV

There is no excerpt because this is a protected post.

comparison-of-the-metabolic-changes-from-the-tango-trial-a-post-hoc-analysis

Comparison of the metabolic changes from the TANGO trial: a post-hoc analysis

There is no excerpt because this is a protected post.

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

The incidence of anal cancer has been increasing over the past decade, but currently still constitutes 0.5% of all cancer diagnoses in the United States. When the cancer has metastasised, prognosis remains poor, with relative 5-year survival rates of approximately 30%. The current standard of care for metastatic anal cancer is cisplatin-based chemotherapy combined with 5-fluorouracil (5-FU). However, no randomised clinical trial investigating the optimal chemotherapy regimen for this disease has been conducted. The InterAAct trial was launched to investigate cisplatin plus FU against carboplatin plus paclitaxel in advanced anal cancers, and full results were recently published in the Journal of Clinical Oncology.